Could traditional Chinese medicine hold an answer to the obesity problem?

January 31, 2013

Obesity might be a very modern problem, but a team of scientists from Taiwan and China is turning to the age-old principles of traditional Chinese medicine (TCM) to help fight it.  Breaking research published in the Journal of Biomolecular Structure and Dynamics indicates a possible new direction for the treatment of metabolic syndrome.

Metabolic syndrome, a collective disorder characterised by obesity and multiple clinical disorders, is on the rise. Obesity itself is an endocrine disease caused by the body's inability to handle excessive energy intake. It can lead to serious like hypertension, osteoarthritis, cardiovascular disease, sleep apnea, stroke and type-2 diabetes.

Peroxisome proliferator-activated receptors (PPARs) are key regulators of lipid and ; they are involved in regulating many physiological functions initiated by nutrients, nutraceuticals and phytochemicals. There are three subtypes of PPARs – PPAR-a, PPAR-g and PPAR-∂ –which all play important roles. Because of these roles, the three are also important for treating metabolic syndrome.

TCM compounds have long been recognised as potential lead candidates in creating anti-viral, anti-tumour and anti-inflammation agents. To see whether they might also be used to design agonists targeting PPAR-a, PPAR-g, and PPAR-∂ in the fight against metabolic disease, the researchers consulted the TCM Database@Taiwan, which lists more than 30,000 small-molecule compounds of TCM origin. The team ran a series of models and simulations to virtually screen the database, establishing structure-based pharmacore models for each PPAR protein in order to identify the key actions during docking; and homology modelling were also performed. The results, published in the Journal of Biomolecular Structure and Dynamics, identify two TCM compounds as potential lead compounds in developing agonists targeting multiple PPARs: (S)-tryptophan-betaxanthin and berberrubine. Further research is needed, but the current study points to an exciting new direction for the treatment of metabolic syndrome.

More information: Chen, K. et al. Three-in-one agonists for PPAR-α, PPAR-γ, and PPAR-δ from traditional Chinese medicine, Journal of Biomolecular Structure and Dynamics, Volume 30, Issue 6, 2012, DOI: 10.1080/07391102.2012.689699

Related Stories

Recommended for you

Blood pressure hormone promotes obesity

July 28, 2016

New research by University of Iowa scientists helps explain how a hormone system often targeted to treat cardiovascular disease can also lower metabolism and promote obesity.

Open-source drug discovery a success

July 28, 2016

In what is being called the first-ever test of open-source drug-discovery, researchers from around the world have successfully identified compounds to pursue in treating and preventing parasite-borne illnesses such as malaria ...

Researchers solve mystery on how regenerative medicine works

July 28, 2016

A study from the University of Pittsburgh School of Medicine and the McGowan Institute for Regenerative Medicine identifies a mechanism by which bioscaffolds used in regenerative medicine influence cellular behavior, a question ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.